Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial

Affiliations

• ¹ Mayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
• ² Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
• ³ Division of Nephrology and Clinical Immunology, Rheinisch-Westfälische Technische Hochschule Aachen University, Aachen, Germany.
• ⁴ Department of Nephrology, 1st Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic.
• ⁵ Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Copenhagen, Denmark.
• ⁶ Department of Medical Sciences, Uppsala University, Uppsala University Hospital, Uppsala, Sweden.
• ⁷ Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy.
• ⁸ Mayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. Electronic address: jb81@leicester.ac.uk.